Trajectories of macrophage ontogeny and reprogramming in cancer

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (5)

Page 1 sur 1

Development of multivalent FAP-targeted Small Molecule-Drug Conjugates with tailored MMAE release kinetics

Dario Neri

Antibody-Drug Conjugates (ADCs) are one of the most diffused targeted therapeutic modalities for cancer treatment and consist of a tumor-targeted monoclonal antibody connected to a cytotoxic payload, which is released selectively at the tumor site. Small M ...

American Association for Cancer Research (AACR)2025

Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis

Sebastian Martin Waszak

MYC-driven group-3 medulloblastomas (MBs) are malignant pediatric brain cancers without cures. To define actionable metabolic dependencies, we identify upregulation of dihydrolipoyl transacetylase (DLAT), the E2-subunit of pyruvate dehydrogenase complex (P ...

Elsevier BV2025

Nanoplastics: Immune Impact, Detection, and Internalization after Human Blood Exposure by Single-Cell Mass Cytometry

Sènan Mickaël Marius Antoine D'Almeida

The increasing exposure to nanoplastics (NPs) raises significant concerns for human health, primarily due to their potential bioaccumulative properties. While NPs have recently been detected in human blood, their interactions with specific immune cell subt ...

2024

Structure and dynamics of Toll immunoreceptor activation in the mosquito Aedes aegypti

Maria Josefina Marcaida Lopez

Aedes aegypti can act as a vector for viral pathogens but the mechanism of viral resistance and evolving host-pathogen tolerance are poorly understood. Here the authors structurally characterise a duplicated pair of interacting Toll immunoreceptors and the ...

Nature Research2022

Elucidating the role of lymphatic vessels within the tumor microenvironment of breast cancer

Ingrid Maria van Mier

Breast cancer is the most common cancer in women worldwide, with an estimated 1.7 million newly diagnosed cases in 2012. Despite the many clinical manifestations, metastatic disease is the main cause of death, and is responsible for 90% of all breast cance ...

EPFL2017